Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic

Abstract

BackgroundHealthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria.MethodsLiposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed.ResultsPalmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32–64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h.ConclusionsOur results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.Electronic supplementary materialThe online version of this article (doi:10.1186/s13104-016-2138-8) contains supplementary material, which is available to authorized users.

Intracellular Staphylococcus aureus Elicits the Production of Host Very Long-Chain Saturated Fatty Acids with Antimicrobial Activity

“…In addition, the combination of fatty acids along with existing therapies may increase their effect and could contribute to the reduction of antimicrobial resistance. The combination of free fatty acids and cholesteryl esters have been recently tested against Pseudomonas aeruginosa and Staphylococcus epidermidis , showing potential as novel antimicrobial agents [48].…”

Nanobiosystems for Antimicrobial Drug-Resistant Infections

“…In the first, LIPs combined with six different fatty acids and four cholesteryl esters were tested against isolates from hospital settings, including VRE. Selected fatty acids and cholesteryl esters in LIPs exhibited antibacterial activity and also enhanced the activity of antibiotics [ 116 ]. In the second case, NPs consisted of block copolymer DA95B5 effectively removed biofilms of various clinically relevant multidrug-resistant bacteria, including MRSA and VRE, in a murine wound model.…”

The Influence of Microbiome Dysbiosis and Bacterial Biofilms on Epidermal Barrier Function in Atopic Dermatitis—An Update

“…Damage to the epidermal barrier triggers the compensatory production of free fatty acids (FFAs) [58]. Physiologically, FFAs show cytotoxic activity and antimicrobial proper-ties [59]. However, as regards AD, FFAs are characterized by shortened fatty acyl chain length and an increased level of unsaturated fatty acids, which compromises their function as factors maintaining epidermal barrier integrity and the homeostasis of the cutaneous microbiota [60].…”